SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.65 HKD | +3.88% |
|
-0.62% | -50.36% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.588
CNY
Average target price
22.5
CNY
Spread / Average Target
+162.01%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.36% | 2.88B | |
| -2.68% | 85.68B | |
| +5.53% | 41.4B | |
| -24.99% | 28.22B | |
| +55.83% | 24.64B | |
| -7.19% | 16.98B | |
| -34.20% | 13.29B | |
| -17.31% | 11.66B | |
| -11.43% | 11.65B | |
| -0.60% | 8.18B |
- Stock Market
- Equities
- 1877 Stock
- News Shanghai Junshi Biosciences Co., Ltd.
- Junshi Biosciences Forms Licensing Deal With UK Drugmaker Hikma
